Marketwatch, July 13, 2021: Fees paid by drug companies make up half of the FDA’s revenue. Dr. Diana Zuckerman explains how these fees often influence FDA decisions and sacrifice patient safety.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Drug Prices Are One Focus of Biden’s Push to Boost Competition
Wall Street Journal, July 9, 2021: Drug prices in the US are extremely high with both sides of the aisle advocating for Medicare to be able to negotiate drug prices. Dr. Diana Zuckerman spoke with the WSJ about how President Biden plans to lower drug prices.
Read More »Emergency Use Authorization vs. Full Approval: What are the Implications?
Contagion Live, June 20, 2021: What is the difference between Emergency Use Authorization and FDA Approval? Dr. Diana Zuckerman addresses the difference between the two and the implications of both.
Read More »New Alzheimer’s drug could be ‘devastating’ for Medicare
Politico, June 15, 2021: The controversial approval of the first drug to target Alzheimer’s disease in nearly 20 years has been blasted by many experts, because the drug is not proven to work and will cost $56,000 per year. “You don’t have to be a rocket scientist to know that the impact on Medicare is likely to be devastating,” said Diana Zuckerman, the president of the National Center for Health Research.
Read More »Alzheimer’s drug approval debacle deepens FDA scrutiny
Politico, June 11, 2021: Dr. Diana Zuckerman speaks with Politico on the impact that the newly approved Alzheimer’s drug will have on Democratic senators.
Read More »